CD19 and neoplasm: After tumor engraftment, mice received i.v. control NT or 10 × 106 CAR.CD19-T cells, followed by the intraperitoneal (i.p.)administration of either control vehicle or 100 mg/kg emapalumab on Day 7, 11, 15, corresponding to the doses used for the non-clinical in vivo pharmacology/toxicology studies of emapalumab.